Home » Posts tagged with » Takeda Pharmaceutical
Takeda gets extended EC approval for ADCETRIS in sALCL

Takeda gets extended EC approval for ADCETRIS in sALCL

Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) in adult patients. The approval from the European Commission (EC) is for the combination of ADCETRIS with CHP (cyclophosphamide, doxorubicin, prednisone. It comes in the wake of a […]

Takeda Pharmaceutical to sell OTC and non-core products to Orifarm

Japan-based Takeda Pharmaceutical has agreed to sell a portfolio of 110 non-core over-the-counter (OTC) and prescription pharmaceutical products it sells in Europe along with a couple of manufacturing plants in Denmark and Poland to Orifarm Group for up to $670 million. As per the terms of the deal, Orifarm will pay nearly $505 million to […]

Continue reading …
Takeda Pharmaceutical acquires celiac disease drug developer PvP Biologics

Takeda acquisition of PvP Biologics : Japanese pharma giant Takeda Pharmaceutical Company has acquired US-based celiac disease drug developer PvP Biologics in a deal worth up to $330 million. The Japanese pharma major exercised its option to acquire the US pharma company following the completion of a phase 1 proof-of-mechanism study of the latter’s investigational […]

Continue reading …
ALTA-1L trial results : Takeda’s ALUNBRIG continues to show superiority over crizotinib

ALTA-1L trial results : Takeda Pharmaceutical says that ALUNBRIG (brigatinib), its tyrosine kinase inhibitor (TKI), is continuing to show superiority over crizotinib in the phase 3 ALTA-1L trial. The Japanese pharma company released updated data from the late-stage trial involving adult patients having advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who did […]

Continue reading …
Takeda Pharmaceutical opens €130m vaccine manufacturing plant in Germany

Takeda Pharmaceutical Company opened a new €130 million vaccine manufacturing plant in Germany at Singen to produce TAK-003, its dengue vaccine candidate. The Singen vaccine manufacturing facility will be used for the formulation, fill, finish and secondary packaging of the TAK-003 dengue vaccine candidate starting with the packaging line. The vaccine plant employs up to […]

Continue reading …
Takeda bags ADCETRIS EC approval for CD30+ Stage IV Hodgkin lymphoma

ADCETRIS EC approval : The European Commission (EC) has expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to cover treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine) in adult patients. ADCETRIS is an antibody-drug conjugate (ADC) that targets CD30, which is a defining marker of […]

Continue reading …
Takeda acquisition of Shire : Japanese pharma company completes $62bn acquisition

Takeda acquisition of Shire : Japanese pharma company Takeda Pharmaceutical wrapped up its previously announced acquisition of Shire, an Irish biotech company with a focus on rare diseases, for $62 billion, as per the latest pharma acquisition news. Takeda acquisition of Shire It was in May 2018 when Takeda agreed to acquire the Irish rare […]

Continue reading …
PvP Biologics initiates Kuma062 human trials for celiac disease treatment

PvP Biologics, a US pharma company, has initiated two phase 1 clinical trials for Kuma062 to evaluate the recombinant enzyme for celiac disease treatment. According to PvP Biologics, Kuma062 has been designed to be active under acidic stomach conditions and it specifically targets the parts of gluten that are behind the autoimmune reaction causing celiac […]

Continue reading …